Latest news-English

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)

1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: Amplification or overexpression of MYC oncoproteins, master regulator of cancers, are observed in over 28% common cancer types. The Technology is a novel aurora kinase inhibitor which was …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03) Read More »

建構生醫價值鏈,加速生醫產業發展!專訪國衛院育成中心蔡熙文主任

台灣有超過上百家育成中心,主要提供新創公司和中小企業在發展前期的資源,其中包含了空間、儀器設備、研發技術、資金連結、商務服務、管理諮詢等,以降低其創業初期的成本與風險。多數育成中心設置在大學與政府機構。其中,國家衛生研究院技轉及育成中心專注於生物科技與醫療衛生領域 ,多年以來更是扮演台灣生醫產業發展的重要推手。

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”(2018/12/17)

Title: NHRI technology, “DBPR211: a peripheral CB1 receptor antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”(2018/12/17) Read More »